Suggested remit: To appraise the clinical and cost effectiveness of Odevixibat (A 4250) within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
|
Status
|
In progress
|
| Process |
HST
|
| ID number |
1570
|
Provisional Schedule
| Committee meeting: 1 |
05 August 2021 |
| Expected publication |
22 January 2022 |
Project Team
| Project lead |
Joanne Ekeledo |
Email enquiries
| Evidence Review Group / Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Consultees
| Companies sponsors |
Albireo (obevixibat) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Addenbrooke's Paediatric Gastrohepatology |
| |
Birmingham Children’s Hospital NHS Foundation Trust |
| |
Department of Endocrinology, University Hospital Birmingham Foundation Trust Paediatric Gastrohepatology |
| |
King’s College Hospital NHS Foundation Trust |
| |
Leeds Teaching Hospitals NHS Trust |
| |
Great Ormond Street Paediatric Gastrohepatology |
| |
Royal Free Paediatric Gastrohepatology |
| |
Welsh Government |
| Patient carer groups |
Action for Sick Children |
| |
Addenbrookes Liver Transplant Association |
| |
British Liver Trust |
| |
Children’s Liver Disease Foundation |
| |
Contact |
| |
Genetic Alliance UK |
| |
Findacure |
| |
Liver4Life |
| |
Metabolic Support UK |
| |
Muslim Council of Great Britain |
| |
National Children’s Bureau |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| Professional groups |
British Association for the Study of the Liver |
| |
British Liver Nurses Forum |
| |
British Society of Gastroenterology |
| |
British Society of Paediatric Gastroenterology, Hepatology and Nutrition |
| |
British Transplantation Society |
| |
Neonatal and Paediatric Pharmacists Group |
| |
Royal College of Physicians |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Paediatrics and Child Health |
| |
Royal Pharmaceutical Society |
| |
UK Clinical Pharmacy Association |
Commentators
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
None |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Hospital Information Services - Jehovah's Witnesses |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
National Services Division (specialised services in Scotland) |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Hepato-Biliary Group |
| |
Foundation for Liver Research |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |
| |
UK National Screening Committee |
|
Date
|
Update
|
|
02 March 2021
|
Invitation to participate |
|
02 March 2021
|
In progress. In progress |
|
15 July 2020 - 12 August 2020
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance